おすすめの製品
グレード
pharmaceutical primary standard
APIファミリー
furosemide
メーカー／製品名
USP
mp
267 °C (dec.) (lit.)
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
SMILES記法
Nc1cc(Cl)c(cc1C(O)=O)S(N)(=O)=O
InChI
1S/C7H7ClN2O4S/c8-4-2-5(9)3(7(11)12)1-6(4)15(10,13)14/h1-2H,9H2,(H,11,12)(H2,10,13,14)
InChI Key
QQLJBZFXGDHSRU-UHFFFAOYSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
アプリケーション
Furosemide Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
アナリシスノート
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
その他情報
Sales restrictions may apply.
関連製品
製品番号
詳細
価格
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
この製品を見ている人はこちらもチェック
F Andreasen et al.
Acta pharmacologica et toxicologica, 49(3), 223-229 (1981-09-01)
Three principles for the use of HPLC with spectrophotometric detection to determine the concentration of furosemide and of 4-chloro-5-sulfamoyl anthranilic acid (CSA) were studied. A reversed phase microbondapack C18 column was used for the separation of either unchanged furosemide (I)
The binding of furosemide to serum proteins in elderly patients: displacing effect of phenprocoumon.
F Andreasen et al.
Acta pharmacologica et toxicologica, 47(3), 202-207 (1980-09-01)
The percentual binding of furosemide (5 micrograms/ml) was slightly but significantly lower in serum from elderly patients than in serum from normal blood donors (96.5 +/- 0.7 versus 97.9 +/- 0.3). A significant positive correlation was demonstrated between protein binding
Thin-layer chromatographic determination of furosemide and 4-chloro-5-sulfamoyl anthranilic acid in plasma and urine.
B Wesley-Hadzija et al.
Journal of chromatography, 229(2), 425-432 (1982-05-14)
H Nakahama et al.
Nephron, 53(2), 138-141 (1989-01-01)
Furosemide is known to potentiate gentamicin nephrotoxicity. The mechanism of potentiation is unclear. In our previous studies, we demonstrated that furosemide enhanced gentamicin accumulation in rabbit renal tissues when injected as a bolus [Kidney int. 33:363, 1988] or repeatedly subcutaneously
H Nakahama et al.
European journal of clinical pharmacology, 32(3), 313-315 (1987-01-01)
Urine from 5 renal transplant recipients treated with frusemide was analyzed for unchanged frusemide (F), glucuronidated frusemide (G) and 4-chloro-5-sulfamoylanthranilic acid (CSA) by HPLC. In 3 recipients, whose renal function recovered steadily and whose hepatic function was normal throughout, the
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）